FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3115673164> ?p ?o ?g. }

• W3115673164 endingPage "2093" @default.
• W3115673164 startingPage "2084" @default.
• W3115673164 abstract "Abstract Background and aims Extended‐release naltrexone (XR‐NTX) is an under‐used treatment option for opioid dependence, today only available in a few countries in the world. Although effective, safe and feasible in short‐term treatment, long‐term data are scarce and there is no recommendation for required treatment length. The aims of the study were to determine the perceived need of long‐term XR‐NTX treatment and to examine long‐term treatment outcomes. Design In this prospective cohort study, following a parent 1‐year study of XR‐NTX, participants received treatment with XR‐NTX at their own discretion for a maximum of 104 weeks. Setting and participants Five urban, outpatient addiction clinics in Norway, comprising opioid‐dependent adults aged 18–60 years ( n = 50) already participating in the parent study. Intervention XR‐NTX administered as intramuscular injections (380 mg) every 4 weeks. Measurements Time in the study, use of opioids and other illicit substances, opioid craving and treatment satisfaction reported every 4 weeks. Findings Among 58 participants who completed the 1‐year parent study, 50 chose to continue the treatment with XR‐NTX. Median prolonged treatment time was 44.0 weeks [95% confidence interval (CI) = 25.5–62.5], ranging from 8 to 104 weeks. Most participants (35, 70%) reported no relapse to opioid use during treatment while a subgroup (15, 30%) reported relapses to opioids during the study. Scores for mean treatment satisfaction and recommending treatment to others were very high (>9) and mean opioid craving score was very low (<1) on a scale ranging from 0 to 10. Conclusions Extended‐release naltrexone (XR‐NTX) was well tolerated in long‐term treatment of opioid‐dependent individuals in Norway already in XR‐NTX treatment. On average, the participants chose to continue treatment for almost 1 year beyond the initial 9–12 months of treatment. Participants reported high treatment satisfaction and 70% showed no relapse to opioids during the treatment period." @default.
• W3115673164 created "2021-01-05" @default.
• W3115673164 creator A5011346756 @default.
• W3115673164 creator A5025775065 @default.
• W3115673164 creator A5029547128 @default.
• W3115673164 creator A5043492442 @default.
• W3115673164 creator A5049858025 @default.
• W3115673164 creator A5058011187 @default.
• W3115673164 creator A5062338649 @default.
• W3115673164 date "2021-01-20" @default.
• W3115673164 modified "2023-10-17" @default.
• W3115673164 title "Adapting treatment length to opioid‐dependent individuals’ needs and preferences: a 2‐year follow‐up to a 1‐year study of extended‐release naltrexone" @default.
• W3115673164 cites W1834705329 @default.
• W3115673164 cites W1880173639 @default.
• W3115673164 cites W1974524186 @default.
• W3115673164 cites W1990391721 @default.
• W3115673164 cites W2006722541 @default.
• W3115673164 cites W2025376268 @default.
• W3115673164 cites W2037459329 @default.
• W3115673164 cites W2052813313 @default.
• W3115673164 cites W2059110077 @default.
• W3115673164 cites W2063836800 @default.
• W3115673164 cites W2074050247 @default.
• W3115673164 cites W2075081854 @default.
• W3115673164 cites W2076078537 @default.
• W3115673164 cites W2079969215 @default.
• W3115673164 cites W2080501091 @default.
• W3115673164 cites W2117613240 @default.
• W3115673164 cites W2142847270 @default.
• W3115673164 cites W2164678034 @default.
• W3115673164 cites W2166258690 @default.
• W3115673164 cites W2248705888 @default.
• W3115673164 cites W2294837683 @default.
• W3115673164 cites W2315631840 @default.
• W3115673164 cites W2327042539 @default.
• W3115673164 cites W2337790923 @default.
• W3115673164 cites W2404633355 @default.
• W3115673164 cites W2508549441 @default.
• W3115673164 cites W2512537769 @default.
• W3115673164 cites W2531840703 @default.
• W3115673164 cites W2539103414 @default.
• W3115673164 cites W2560420609 @default.
• W3115673164 cites W2598180328 @default.
• W3115673164 cites W2598796960 @default.
• W3115673164 cites W2601289664 @default.
• W3115673164 cites W2742729961 @default.
• W3115673164 cites W2766969415 @default.
• W3115673164 cites W2768214444 @default.
• W3115673164 cites W2803611658 @default.
• W3115673164 cites W2805471207 @default.
• W3115673164 cites W2912439666 @default.
• W3115673164 cites W2962729260 @default.
• W3115673164 cites W2982097977 @default.
• W3115673164 cites W2999564057 @default.
• W3115673164 cites W3000475066 @default.
• W3115673164 doi "https://doi.org/10.1111/add.15378" @default.
• W3115673164 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8359292" @default.
• W3115673164 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33338285" @default.
• W3115673164 hasPublicationYear "2021" @default.
• W3115673164 type Work @default.
• W3115673164 sameAs 3115673164 @default.
• W3115673164 citedByCount "3" @default.
• W3115673164 countsByYear W31156731642022 @default.
• W3115673164 crossrefType "journal-article" @default.
• W3115673164 hasAuthorship W3115673164A5011346756 @default.
• W3115673164 hasAuthorship W3115673164A5025775065 @default.
• W3115673164 hasAuthorship W3115673164A5029547128 @default.
• W3115673164 hasAuthorship W3115673164A5043492442 @default.
• W3115673164 hasAuthorship W3115673164A5049858025 @default.
• W3115673164 hasAuthorship W3115673164A5058011187 @default.
• W3115673164 hasAuthorship W3115673164A5062338649 @default.
• W3115673164 hasBestOaLocation W31156731641 @default.
• W3115673164 hasConcept C118552586 @default.
• W3115673164 hasConcept C126322002 @default.
• W3115673164 hasConcept C141071460 @default.
• W3115673164 hasConcept C170493617 @default.
• W3115673164 hasConcept C2775944032 @default.
• W3115673164 hasConcept C2777972943 @default.
• W3115673164 hasConcept C2779418921 @default.
• W3115673164 hasConcept C2779541405 @default.
• W3115673164 hasConcept C2781063702 @default.
• W3115673164 hasConcept C44249647 @default.
• W3115673164 hasConcept C48856860 @default.
• W3115673164 hasConcept C71924100 @default.
• W3115673164 hasConceptScore W3115673164C118552586 @default.
• W3115673164 hasConceptScore W3115673164C126322002 @default.
• W3115673164 hasConceptScore W3115673164C141071460 @default.
• W3115673164 hasConceptScore W3115673164C170493617 @default.
• W3115673164 hasConceptScore W3115673164C2775944032 @default.
• W3115673164 hasConceptScore W3115673164C2777972943 @default.
• W3115673164 hasConceptScore W3115673164C2779418921 @default.
• W3115673164 hasConceptScore W3115673164C2779541405 @default.
• W3115673164 hasConceptScore W3115673164C2781063702 @default.
• W3115673164 hasConceptScore W3115673164C44249647 @default.
• W3115673164 hasConceptScore W3115673164C48856860 @default.
• W3115673164 hasConceptScore W3115673164C71924100 @default.
• W3115673164 hasFunder F4320322496 @default.
• W3115673164 hasFunder F4320323260 @default.

• next